Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
TEM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.89 - $91.45
Previous CloseN/A
Volume1.41M
Average Volume (3M)12.89M
Market Cap
$8.24B
Enterprise Value$5.49B
Total Cash (Recent Filing)$340.95M
Total Debt (Recent Filing)$468.09M
Price to Earnings (P/E)―
Beta5.44
Next Earnings
Aug 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.75
Shares Outstanding167,168,910
10 Day Avg. Volume10,729,562
30 Day Avg. Volume12,891,847
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.06
Price to Cash Flow (P/CF)45.40
P/FCF Ratio35.30
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.41
Enterprise Value/Ebitda-9.00
Forecast
1Y Price Target
$64.13Price Target Upside34.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Business PerformanceThe company's clinical oncology business showed strong performance with revenue increasing by 35% and volumes growing by 23%.
Profitability OutlookTempus is now expecting to reach EBITDA profitability a year ahead of prior expectations, which is viewed positively given the challenges digital health companies face in achieving profitability.
Strategic AcquisitionThe acquisition of Ambry is expected to contribute mid-to-high teens growth, leading to positive adj. EBITDA for the combined business in FY25.
Bears Say
Growth ConcernsAmbry's slower long-term revenue growth is dilutive to TEM's standalone long-term growth rate.
Market ReactionInvestors may be underwhelmed by the magnitude of the beat and raise, as evidenced by the stock being down ~13% in premarket.
Revenue ExpectationsPreliminary Q4 results were slightly below expectations, which may have caused some concern among investors.
---
Ownership Overview
45.40% Insiders
2.49% Mutual Funds
21.82% Other Institutional Investors
25.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $22.89 and its highest was $91.45 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $8.24B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 12, 2025 which is in 133 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Feb 24, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.156 by -$0.024.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Undervalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 167,168,910 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.156. Following the earnings report the stock price went down -15.05%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
---
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.13 (34.08% Upside)
$64.13 (34.08% Upside)
Blogger Sentiment
Bullish
TEM Sentiment 90%
Sector Average 75%
Sector Average 75%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $223.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-1252.79%
Trailing 12-Months
Asset Growth
64.19%
Trailing 12-Months
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
---
TEM Company Deck
---
TEM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue and gross profit growth, successful strategic acquisitions, and positive future guidance. Despite some minor challenges with data delivery timing and adjusted growth expectations for Ambry Genetics, the overall outlook remains positive with significant achievements in AI diagnostics reimbursement and strategic partnerships.Read More>---
TEM Stock 12 Month Forecast
Average Price Target
$64.13
▲(34.08% Upside)
Technical Analysis
Best Analysts Covering TEM
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+20.08%
reiterated a buy rating last month
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +20.08% per trade.
---